Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.

MLA

Thiruvengadam, Ramachandran, et al. “Effectiveness of ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2 Infection during the Delta (B.1.617.2) Variant Surge in India: A Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses.” Lancet Infectious Diseases, vol. 22, no. 4, Apr. 2022, pp. 473–82. EBSCOhost, https://doi.org/10.1016/S1473-3099(21)00680-0.

APA

Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., & Ahmad Khan, N. (2022). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infectious Diseases, 22(4), 473–482. https://doi.org/10.1016/S1473-3099(21)00680-0

Chicago

Thiruvengadam, Ramachandran, Amit Awasthi, Guruprasad Medigeshi, Sankar Bhattacharya, Shailendra Mani, Sridhar Sivasubbu, Tripti Shrivastava, et al. 2022. “Effectiveness of ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2 Infection during the Delta (B.1.617.2) Variant Surge in India: A Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses.” Lancet Infectious Diseases 22 (4): 473–82. doi:10.1016/S1473-3099(21)00680-0.